Skip to main content

Financial News

  • Fred’s Pharmacy sees progress in specialty pharmacy sales

    MEMPHIS, Tenn. — Fred’s Pharmacy saw total sales for the month of January decline 5.6% year over to $148.1 million from $156.9 million. Comparable-store sales for the month decreased by 4.8% versus an increase of 0.7% during the prior year period.

    As for its 2016 fourth quarter, total sales for the fourth quarter of 2016 decreased 4.3% year over year to $530.7 million from $554.6 million in the fourth quarter of 2015. On a comparable-store basis, Q4 sales decreased 3.6% versus an increase of 1.7% in the year-earlier period.

  • Healthcare system sees more than $1T in savings during past decade

    Generics have made a huge difference to the U.S. healthcare system’s bottom line in the past decade, a savings that takes 13 figures to tabulate.

    (To view the full Category Review, click here.)

  • New contenders, category heavyweights battle for top spot in cough-cold

    Last year, Drug Store News projected that GSK Consumer Healthcare’s Flonase allergy franchise would be challenged with the introduction of two new nasal corticosteroids to the market — McNeil Consumer’s Rhinocort and Bayer’s ClariSpray.

    (To view the full Cough-Cold Report, click here.)

  • Analyst: ‘Still chance of a reasonable outcome’ for Walgreens-Rite Aid deal

    NEW YORK — An Evercore ISI analyst maintained his “buy” rating on Walgreens Boots Alliance stock, stating that although its proposed deadline for a deal with Rite Aid has been delayed, “there is still a chance of a reasonable outcome for both parties.”

    The companies pushed back the deadline for merger from Jan. 27 to July 31 and trimmed the purchase price paid to Rite Aid to $6.50 to $7 per share — based upon the number of store divestitures the FTC requires — from $9 per share.

  • S&P Global expects busy 2017 for mergers and acquisitions

    NEW YORK — 2017 will be another busy year for merger and acquisition activity in the U.S., S&P Global Ratings stated in its latest report.

    President Trump’s plans for lower corporate taxes, repatriation of cash held abroad, and a most business-friendly climate bode well for deal making, S&P wrote in its new report, “New Administration Could Spur M&A Activity, But Antitrust Regulation is Not Going Away.”

  • Walgreens, Rite Aid amend deal to $7 per share, extend end date

    DEERFIELD, Ill.  — Walgreens Boots Alliance and Rite Aid on Monday morning extended their previously announced definitive merger agreement under which Walgreens Boots Alliance will acquire all outstanding shares of Rite Aid.

  • Prestige Brands completes C.B. Fleet acquisition

    TARRYTOWN, N.Y. — Prestige Brands completed its previously announced acquisition of C.B. Fleet for $825 million.

     As part of the transaction, Prestige Brands acquired multiple feminine hygiene, gastrointestinal care and infant care over-the-counter brands, including Summer's Eve, Fleet, and Pedia-Lax, as well as a "mix and fill" manufacturing facility in Lynchburg Va. 

    The merger was first announced on Dec. 22. Prestige Brands announced the transaction was completed via a Form 8-K filed with the U.S. Securities and Exchange Commission.

  • Walgreens increases regular quarterly dividend

    DEERFIELD, Ill.  — Walgreens Boots Alliance on Thursday announced that its board of directors has declared a regular quarterly dividend of 37.5 cents per share, an increase of 4.2% over the year-ago period.

    Walgreens Boots Alliance and its predecessor company, Walgreens, have paid a dividend in 337 straight quarters (more than 84 years) and have raised the dividend for 41 consecutive years.

    The dividend is payable March 10, 2017 to stockholders of record as of Feb. 15, 2017.

     

X
This ad will auto-close in 10 seconds